Gilead’s Remdesivir shows promising results

Gilead’s Remdesivir shows promising results

Gilead stocks traded higher today as the clinical trial for Remdesivir was a success.

The latest data from the National Institute of Allergy and Infectious Diseases shows promising results from Gilead's drug. Also, Gilead itself released the results of its study, showing an improvement in health for patients who took the drug.

The new data comes just a few days after a report was released by mistake by the World Health Organization. That specific report showed no difference between Remdesivir users and the control group, basically rendering the drug nothing more than placebo.

However, today’s release from Gilead shows that, since the beginning of trials, the drug was effective among patients within the early phase of Covid-19.

At that time, the stock price dropped by 5.3%. Today, it gained more than it initially lost, 5.4%.

The market did not overthink and acted accordingly: USA30 traded higher by 1.5%. USA500 gained 1.9%, while TECH100 went up 2.1%. It was a change for the better after the terrible GDP report which hit the markets earlier.

See the difference when trading with CAPEX.com by accessing elite features:

  • Stellar custom service
  • Powerful WebTrader platform and mobile app
  • High-end integrated trading tools
  • Full license and regulation from top regulators


Sources cnbc.com, Bloomberg.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation. Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.


La información presentada aquí está preparada por CAPEX.com y no pretende constituir un asesoramiento de inversión. La información aquí se proporciona como una comunicación general de marketing con propósitos solo de información, y como tal, no se han preparado de acuerdo con los requisitos legales diseñados para promover la independencia de un estudio de inversión, y no está sujeto a ninguna prohibición para hacer frente con antelación a la diseminación de los análisis de inversión.

Los usuarios / lectores no deben confiar únicamente en la información presentada aquí y deben hacer su propia investigación / análisis leyendo también la investigación subyacente real. El contenido adjunto es genérico y no tiene en cuenta las circunstancias personales, la experiencia de inversión o la situación financiera actual.

Por lo tanto, Key Way Investments Ltd no aceptará ninguna responsabilidad por las pérdidas de los comerciantes debido al uso y el contenido de la información presentada en este documento. El rendimiento pasado no es un indicador confiable de resultados futuros.